



Suite 240, 1650 Fillmore Street, Denver, CO 80206, USA.
Tel: 303-322-2254 Fax: 303-322-2257 E-mail: ashley@cytoskeleton.com

August 31, 2001

David Lukton
Commissioner of Patents
USPTO
Patent Applications
Washington DC 20231

Ref: 09/725,030

Dear David Lukton:

In response to your e-mail dated 10.12am 8-27-2001, we would like to make a Preliminary Amendment to the claims. The following claims are hereafter deleted:

1. Claims 1 and 2 are deleted.

In addition we would like to make a Preliminary Amendment to change the following claims:

Claim 3: Change to Claim 1 - A tubulin ligand that causes an S-phase arrest mechanism of anti-cancer activity, this is a two component mixture i.e. cancer cells inhibited by a tubulin ligand.

Claim 4: Change to Claim 2 - In combination with Claim 1, where the tubulin ligand is iodine acetamido benzoyl ethyl acetate.

Claim 5: Change to Claim 3 - In combination with Claim 1, where the tubulin ligand is bromine acetamido benzoyl ethyl acetate.

Claim 6: Change to Claim 4 - In combination with Claim 1, where the tubulin ligand is a derivative of an halogenated acetamido benzoyl ethyl acetate.

Claim 7: Change to Claim 5 - In combination with Claim 1, a compound that may have therapeutic potential in treating diseases such as fungal infections, viral infections, parasitic infections, gout, restenosis, multiple sclerosis, Parkinson's and Alzheimer's diseases.

There is one species election, that is halogenated acetamido benzoyl ethyl acetate.

I did not quite understand your request for three or two component mixture - so if it does not sound quite right in the amended Claim 1 then let me know. E-mail is a good way to reach me - thank you.

Yours sincerely,

Ashley Davis, Cytoskeleton Inc.